Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

被引：4
|
作者：
Schadendorf, D. [1 ]
Wolchok, J. [2 ]
Neyns, B. [3 ]
Lebbe, C. [4 ]
Harmankaya, K. [5 ]
Verschraegen, C. [6 ]
Chin, K. [7 ]
de Pril, V. [8 ]
Hoos, A. [7 ]
Maio, M. [9 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Univ Ziekenhuis St Rafael, Dept Oncol, Brussels, Belgium
[4] Hop St Louis, Dept Dermatol, Paris, France
[5] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[6] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA
[7] Bristol Myers Squibb Co, Global Clin Res Oncol, Wallingford, CT 06492 USA
[8] Bristol Myers Squibb Co, Global Biometr & Sci, Braine Lalleud, Belgium
[9] Univ Hosp Siena, Dept Oncol, Siena, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71952-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [21] Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
    Ascierto, P. A.
    Del Vecchio, M.
    Robert, C.
    Mackiewicz, A.
    Chiarion-Sileni, V.
    Arance Fernandez, A. M.
    Schmidt, H.
    Lebbe, C.
    Bastholt, L.
    Hamid, O.
    Rutkowski, P.
    McNeil, C.
    Garbe, C.
    Loquai, C.
    Dreno, B.
    Thomas, L.
    Grob, J. J.
    Hennicken, D.
    Qureshi, A.
    Maio, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Ipilimumab Improves Overall Survival in Previously Treated, Advanced Melanoma Patients with Good and Poor Prognostic Factors
    O'Day, Steven J.
    McDermott, David F.
    Urba, Walter J.
    Wolchok, Jedd D.
    Robert, Caroline
    Haanen, John B.
    Dummer, Reinhard
    Messina, Marianne
    Hoos, Axel
    Hodi, F. Stephen
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 905 - 906
  • [23] Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
    Altomonte, Maresa
    Di Giacomo, Anna Maria
    Queirolo, Paola
    Ascierto, Paolo Antonio
    Spagnolo, Francesco
    Bajetta, Emilio
    Calabro, Luana
    Danielli, Riccardo
    de Rosa, Francesco
    Maur, Michela
    Chiarion-Sileni, Vanna
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Testori, Alessandro
    Ridolfi, Ruggero
    Maio, Michele
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
  • [24] Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
    Maresa Altomonte
    Anna Maria Di Giacomo
    Paola Queirolo
    Paolo Antonio Ascierto
    Francesco Spagnolo
    Emilio Bajetta
    Luana Calabrò
    Riccardo Danielli
    Francesco de Rosa
    Michela Maur
    Vanna Chiarion-Sileni
    Pier Francesco Ferrucci
    Diana Giannarelli
    Alessandro Testori
    Ruggero Ridolfi
    Michele Maio
    Journal of Experimental & Clinical Cancer Research, 32
  • [25] CLINICAL ACTIVITY OF IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA AND BRAIN METASTASES
    Weber, J. S.
    Berman, D.
    Siegel, J.
    Minor, D.
    Maraveyas, A.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2008, 19 : 244 - 244
  • [26] P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level
    Smylie, M.
    Kaehler, K. C.
    Francis, S.
    Nyens, B.
    Maio, M.
    Minor, D.
    Verschraegen, C.
    Chin, K.
    Ibrahim, R.
    Hoos, A.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (09): : 836 - 836
  • [27] Exposure-Response (E-R) Analysis to Support Benefit-Risk Assessment of Ipilimumab 3 vs 10 mg/kg in Patients with Advanced Melanoma
    Vezina, Heather E.
    Wang, Shelly
    Statkevich, Paul
    Bello, Akintunde
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S34 - S34
  • [28] Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing)
    Urba, W. J.
    Weber, J. S.
    O'Day, S. J.
    Powderly, J. D.
    Yellin, M. J.
    Nichol, G.
    Hersh, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
    Hamid, O.
    Chasalow, S. D.
    Tsuchihashi, Z.
    Alaparthy, S.
    Galbraith, S.
    Berman, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] The Baseline Tumor Size is an independent prognostic Factor for the progression-free but not the Overall Survival after Ipilimumab in Patients with metastatic malignant Melanoma
    Angelova, D.
    Weide, B.
    Heppt, M.
    Berking, C.
    Tietze, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 76 - 76
12345